rivastigmine has been researched along with masoprocol in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ibrar, A; Khan, I; Saeed, F; Shehzadi, SA | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
1 review(s) available for rivastigmine and masoprocol
| Article | Year |
|---|---|
Developing hybrid molecule therapeutics for diverse enzyme inhibitory action: Active role of coumarin-based structural leads in drug discovery.
Topics: Aldehyde Reductase; Alkaline Phosphatase; Cholinesterases; Coumarins; Drug Design; Enzymes; Glucosidases; Humans; Molecular Docking Simulation; Monoamine Oxidase | 2018 |
1 other study(ies) available for rivastigmine and masoprocol
| Article | Year |
|---|---|
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |